NLE Gastrointestinal Nursing — Upper GI & Esophageal DisordersSummary

Correct assessment order is critical: **Inspection → Auscultation → Percussion → Palpation**. Auscultation must precede palpation because manual palpation stimulates the abdomen and alters bowel sound frequency, leading to inaccurate findings. Inspection evaluates contour (flat, rounded, distended), symmetry, visible peristalsis, pulsations, and surgical scars. Auscultation in all four quadrants establishes normal (5–35 per minute), hyperactive (borborygmi, suggesting early obstruction or diarrhea), or hypoactive/absent (ileus, peritonitis, late obstruction—listen 5 minutes minimum before documenting absence). Percussion detects tympany over gas-filled bowel versus dullness over solid organs. Palpation, performed last, assesses tenderness, guarding, rigidity, rebound tenderness, and masses.

GERD results from **incompetent lower esophageal sphincter (LES) function**, allowing **retrograde flow of acidic gastric contents into the esophagus**. The LES normally maintains a pressure of 10–30 mmHg; when this pressure drops below 10 mmHg or transient relaxations occur, especially in supine or postprandial positions, acid refluxes and irritates the non-keratinized squamous epithelium of the esophagus. Chronic exposure causes **reflux esophagitis** (mucosal inflammation and erosion). Over time, metaplastic columnar epithelium replaces the native squamous lining—a condition called **Barrett's esophagus**, which is **premalignant** and significantly increases the risk of esophageal adenocarcinoma (1,000-fold higher risk than the general population).

Typical presentation includes **pyrosis (heartburn)**—retrosternal burning pain worse after meals, when lying down, or bending over—along with **regurgitation** of acidic/bitter material, chronic cough, hoarseness, dysphagia, and nocturnal symptoms disrupting sleep. GERD often mimics acute coronary syndrome; therefore, **cardiac ischemia must be ruled out first** in any patient with chest pain, especially in those with cardiac risk factors. **24-hour ambulatory pH monitoring** is the **gold standard diagnostic test**, recording esophageal pH to document acid exposure. **Upper endoscopy (esophagogastroduodenoscopy, EGD)** visualizes mucosal injury and screens for Barrett's esophagus or other complications. Esophageal manometry assesses LES resting pressure and peristaltic function.

**First-line management** emphasizes behavioral modification: (1) **Elevate the head of the bed 15–20 cm (6–8 inches)** using a wedge pillow or bed blocks to prevent nocturnal reflux; (2) **remain upright for 2–3 hours after eating**; (3) eat **small, frequent meals** rather than large meals that overdistend the stomach; (4) **avoid eating within 3 hours of bedtime**. **Trigger foods** (those that lower LES tone or increase gastric acid) must be identified and avoided: **fatty/fried foods, chocolate, caffeine, alcohol, peppermint, citrus fruits, tomato products, and carbonated beverages**. **Smoking cessation** and **weight loss** (if overweight) improve LES competence. Pharmacologically, **proton pump inhibitors (PPIs) are first-line**—omeprazole 20–40 mg daily, pantoprazole 40 mg daily, esomeprazole 20–40 mg daily, or lansoprazole 30 mg daily, taken **30–60 minutes BEFORE the first meal** to inhibit the activated proton pump. H2-receptor antagonists (famotidine 20–40 mg at bedtime) are less potent alternatives. Antacids provide rapid but short-term relief.

A **hiatal hernia** is protrusion of part of the stomach through the diaphragmatic hiatus into the thorax. The **sliding type (Type I, ~90% of cases)** involves intermittent upward displacement of the gastroesophageal junction and presents with GERD-like symptoms (heartburn, regurgitation). The **rolling/paraesophageal type (Type II/III, ~10%)** involves herniation of the gastric fundus alongside the esophagus; the esophagogastric junction remains below the hiatus. Rolling hernias risk **volvulus and strangulation**—a **surgical emergency** presenting with severe epigastric pain, vomiting, and potential hemorrhage. Management for sliding hernias mirrors GERD (positioning, small meals, acid suppression). Rolling hernias typically require **Nissen fundoplication** (surgical wrapping of the fundus around the esophagus to reinforce the LES) or **Hill repair**. Patient education includes avoiding heavy lifting, straining, and constipation—activities that increase intra-abdominal pressure and exacerbate herniation.

A **peptic ulcer** is a focal defect in the mucosa of the **stomach (gastric ulcer)** or **duodenum (duodenal ulcer)** that penetrates through the muscularis mucosae, exposed to acid and pepsin. The ulcer develops when **acid-pepsin secretion overwhelms mucosal protective mechanisms** (bicarbonate secretion, mucus layer, prostaglandins, mucosal blood flow). The two major causes are ***Helicobacter pylori* infection** (a gram-negative bacterium that colonizes the gastric antrum, triggering chronic inflammation) and **NSAID use** (including aspirin, which inhibit protective prostaglandins). Contributing factors include smoking, alcohol excess, corticosteroid use, severe physiologic stress, and psychological stress. **Contrary to the outdated "no acid, no ulcer" belief, most ulcers occur in the setting of normal or even low acid secretion**; the critical factor is inadequate mucosal protection.

**GASTRIC ULCER:** Pain typically occurs **30–60 minutes after eating**; food **WORSENS or does not relieve** the pain. **Weight loss** is common because patients eat less to avoid pain. Malignancy risk is higher (~2–5% of gastric ulcers are malignant), so any gastric ulcer requires endoscopic surveillance for healing and to rule out adenocarcinoma. **DUODENAL ULCER:** Pain characteristically occurs **2–3 hours after eating or at night**, often awakening the patient. **Food or antacids RELIEVE the pain**—patients frequently gain weight because they eat frequently to buffer acid. Malignancy risk is negligible (the duodenum is not a site for gastric cancer). This classic distinction guides both diagnosis and patient counseling and is a high-frequency NLE testing point.

***H. pylori* diagnostic methods:** (1) **Urea breath test (UBT)**—patient ingests labeled urea; if H. pylori is present, urease cleaves it to labeled CO2, absorbed and exhaled, then measured—highly sensitive (~95%) and specific (~98%). (2) **Stool antigen test**—detects bacterial antigen in stool; non-invasive but slightly less sensitive. (3) **Biopsy-based tests during endoscopy—rapid urease test (RUT), histology, or culture**—gold standard for diagnosis but requires endoscopy. (4) **Serology (IgG antibody)**—indicates past or current exposure but does NOT distinguish active infection; hence less useful for initial diagnosis but may be used epidemiologically. **CRITICAL TESTING PRECAUTION:** PPIs inhibit H. pylori growth and may cause false-negative results; patients must **stop PPIs 2 weeks before UBT or stool testing**. Antibiotics and bismuth compounds must be **discontinued 4 weeks prior**. This detail appears frequently in NLE pharmacology and diagnostic sections.

**Standard triple therapy (14 days):** PPI (twice daily) + clarithromycin 500 mg twice daily + amoxicillin 1 g twice daily. For **penicillin-allergic patients**, substitute **metronidazole 500 mg twice daily** for amoxicillin. **Bismuth quadruple therapy (10–14 days)** is used for treatment failure or clarithromycin-resistant strains: PPI + bismuth subsalicylate + tetracycline + metronidazole. **Key nursing points:** (1) **Emphasize FULL course completion** (non-adherence drives resistance and treatment failure). (2) **Metronidazole** requires **absolute alcohol avoidance**—concurrent use triggers a **disulfiram-like reaction** (flushing, nausea, vomiting, tachycardia, hypotension) due to acetaldehyde accumulation. Patients must avoid all alcohol-containing products (mouthwash, cough syrups, some medications). (3) **Metronidazole** commonly causes a **metallic taste** (reassure patient this is harmless and transient). (4) **Bismuth** darkens the stool and tongue black/gray (cosmetic, harmless—critical to inform patients to prevent anxiety). (5) **Monitor for adverse effects:** clarithromycin and amoxicillin may cause diarrhea; metronidazole may cause peripheral neuropathy with prolonged use.

**Typical presentation:** Gnawing or burning **epigastric pain** with associated dyspepsia. Timing relative to meals and response to food/antacids guide differentiation of gastric vs. duodenal ulcer (see key concept above). **Diagnostic gold standard:** **Upper endoscopy (EGD)** with biopsy—visualizes the ulcer, assesses depth/size, rules out malignancy (especially for gastric ulcers), and allows biopsy for *H. pylori* testing or histologic confirmation. **Complications—often dramatic presentations:** (1) **Hemorrhage**—the most common complication; presents with hematemesis (bright red blood or coffee-ground material), melena (black, tarry, sticky stool), or occult bleeding with anemia. (2) **Perforation**—sudden onset of severe, **rigid "board-like" abdomen** with peritoneal signs (rebound, guarding); a **surgical emergency** requiring immediate NPO status, IV access, nasogastric decompression, and surgical exploration. (3) **Gastric outlet obstruction**—chronic ulcers cause scarring/stenosis; presents with early satiety, postprandial vomiting (possibly projectile), weight loss, and dehydration. (4) **Iron-deficiency anemia** from chronic occult bleeding. These complications transition PUD from medical to surgical management.

**Assessment (focused history & physical):** Elicit onset, duration, and characteristics of hematemesis (bright red vs. coffee-ground, volume); melena or hematochezia; associated symptoms (abdominal pain, dizziness, syncope, dyspnea). Assess **cardiovascular compensation**: tachycardia, hypotension (systolic <90 mmHg indicates significant volume loss), cool clammy skin, weak pulses. Monitor **urine output** (oliguria <0.5 mL/kg/h suggests shock). Check serial hemoglobin/hematocrit (initial hemoglobin may be normal in acute bleeding until compensatory hemodilution occurs). **ABC Priority Interventions (Maslow Level 2—Safety & Physiologic Needs):** (1) **Airway & Breathing:** Assess for signs of aspiration; position patient upright or left lateral to protect airway; provide high-flow oxygen. (2) **Circulation:** Establish **two large-bore IV lines (18-gauge or larger)** for rapid fluid resuscitation. Initiate **isotonic IV fluids (0.9% normal saline or lactated Ringer's solution)** at wide-open rates initially; avoid hypotonic fluids (increase cerebral edema risk). **Type and crossmatch** for potential transfusion. Monitor vital signs and urine output continuously. Transfuse packed red blood cells per protocol if Hgb <7 g/dL (or <8 g/dL in elderly/cardiac patients). (3) **NPO status** (aspiration precaution and anticipating endoscopy). (4) **Insert nasogastric tube** (if no perforation suspected) for gastric decompression and monitoring of continued bleeding; connect to **low intermittent suction**. (5) **Prepare for emergency upper endoscopy** for diagnosis and therapeutic intervention (variceal banding, epinephrine injection, cautery, clip placement). (6) **IV PPI infusion** (e.g., pantoprazole 80 mg bolus then 8 mg/h infusion) to reduce acid and optimize clot stability.

The **leading causes** (in approximate order of frequency) are: (1) **Peptic ulcer disease** (most common, ~40–50% of cases)—erosion into a vessel, typically the gastroduodenal artery in duodenal ulcers or left gastric artery in gastric ulcers. (2) **Esophageal/gastric varices**—dilated submucosal veins from portal hypertension (cirrhosis, portal vein thrombosis); rupture causes massive, life-threatening hemorrhage. (3) **Erosive gastritis/esophagitis**—mucosal erosions from NSAIDs, alcohol, stress, or severe reflux; typically cause oozing rather than massive bleeding. (4) **Mallory-Weiss tear**—linear mucosal tear at the gastroesophageal junction or distal esophagus, often following forceful/repeated vomiting (especially in alcoholic patients with retching); classically presents with hematemesis after an episode of non-bloody vomiting. (5) **Boerhaave syndrome** (esophageal perforation)—rare but catastrophic, typically from forceful vomiting or instrumentation; presents with chest pain, subcutaneous emphysema, and sepsis. Rarer causes include angiodysplasia, gastric cancer, and Dieulafoy lesion (a small arterial malformation).

**Gastritis** is inflammation of the gastric mucosa. **Acute gastritis** develops rapidly from NSAIDs, alcohol, spicy food, *H. pylori* infection, or severe physiologic stress (stress-related mucosal disease). Presents with epigastric discomfort, dyspepsia, nausea, and possibly hematemesis (if erosion occurs). Usually self-limited; management includes removing the offending agent and acid suppression (PPIs/H2 blockers). **Chronic gastritis**, often from persistent *H. pylori* infection or **autoimmune destruction of gastric parietal cells**, leads to chronic mucosal inflammation and **loss of intrinsic factor (IF)**. Intrinsic factor is essential for **vitamin B12 (cobalamin) absorption** in the terminal ileum; without it, vitamin B12 deficiency develops, causing **pernicious anemia** (megaloblastic, with neurologic sequelae if untreated: paresthesias, ataxia, dementia). Diagnosis: anti-parietal cell or anti-intrinsic factor antibodies; low B12 with elevated methylmalonic acid/homocysteine. **Treatment: lifelong intramuscular B12 injections** (oral B12 is ineffective without intrinsic factor) at doses of 1000 µg monthly or every 3 months, depending on clinical response.

Critically ill patients develop acute gastric mucosal erosions (not true ulcers, as they don't penetrate the muscularis) from **mucosal ischemia** and **acid-pepsin injury** in the setting of shock, hypoperfusion, or severe systemic illness. High-risk populations include: **Curling's ulcers** (extensive burns, from severe stress hormone release and splanchnic vasoconstriction); **Cushing's ulcers** (head trauma or raised intracranial pressure, from vagal stimulation increasing acid); patients on mechanical ventilation, with coagulopathy, sepsis, or multiorgan failure. **Prophylaxis is standard** in ICU settings: a **PPI (e.g., pantoprazole 40 mg daily) or H2 blocker (famotidine 20 mg twice daily)** is administered to all high-risk ICU patients. **Early enteral nutrition (when tolerated)** provides mucosal blood flow support. Treating the underlying shock/infection and maintaining adequate perfusion is equally critical. Most stress ulcers respond to prophylaxis; overt bleeding is rare now due to widespread PPI use.

**Insertion technique:** (1) Measure length: **Nose–Earlobe–Xiphoid (NEX)** distance to estimate insertion depth. (2) Position patient with **head flexed slightly forward** (to facilitate passage through the pharynx and reduce risk of tracheal placement). (3) Lubricate the tube with water-soluble lubricant. (4) Insert gently, advancing as patient **swallows or sips water** to ease passage into the esophagus (swallowing elevates the epiglottis, protecting the airway). (5) If patient coughs, chokes, or cannot speak—**STOP immediately and withdraw the tube** (indicates possible airway placement). **Placement verification (CRITICAL—a high-yield NLE topic):** (1) **Bedside pH testing (most reliable bedside method):** Aspirate gastric contents and test with pH paper; **gastric aspirate pH ≤ 5.5** confirms gastric placement. (2) **X-ray (gold standard):** Confirms tube position in the stomach (not duodenum or colon). (3) **Auscultation (air-bolus method—NO LONGER RECOMMENDED alone):** Historical method of listening for a "whoosh" when 10–20 mL air is injected is **unreliable** (air can pass through tubes in the lung or colon); do not use as sole verification. (4) **Visual inspection of aspirate:** Gastric aspirate is typically clear, cloudy, tan, green, or blood-tinged; duodenal fluid is bile-stained (golden/green). **Maintenance & monitoring:** Keep the **head of bed elevated 30–45°** (prevents aspiration). Check for **tube patency** before each use and feeding. Monitor **residual volume** for feeding tubes (typically <250 mL in adults); high residuals suggest delayed gastric emptying. For decompression tubes (obstruction, post-op ileus), connect to **low intermittent suction** and monitor drainage color/amount (important for assessing ongoing bleeding or electrolyte loss). Document tube placement, patency, residual volumes, and drainage characteristics.

**Proton pump inhibitors (PPIs)—first-line for acid suppression:** Irreversibly inhibit the H+/K+-ATPase (proton pump) in gastric parietal cells. **Drugs & doses:** Omeprazole 20–40 mg once daily, pantoprazole 40 mg once daily, esomeprazole 20–40 mg once daily, lansoprazole 30 mg once daily. **Timing critical:** Take **30–60 minutes BEFORE the first meal**—the drug requires an activated proton pump (activated by food intake) to be effective. Bioavailability decreases if taken with food. **Efficacy:** Reduce acid by >90%; healing rates for PUD are >90% within 4–8 weeks. **Adverse effects (chronic use):** Hypomagnesemia (rare but serious; can cause cardiac arrhythmias), vitamin B12 deficiency (reduced intrinsic factor activity), decreased calcium absorption (↑ fracture risk), and **increased *Clostridioides difficile* risk** (altered gut flora from prolonged acid suppression). **Long-term monitoring:** Check magnesium and B12 annually in chronic users. **H2-receptor antagonists:** Reduce acid by ~70%; examples include famotidine 20–40 mg twice daily (ranitidine was withdrawn due to NDMA contamination). **Timing:** Can be taken with meals; bedtime dosing is effective for nocturnal acid. Less potent than PPIs; reserved for mild GERD or as adjunct therapy. **Antacids:** Neutralize existing acid rapidly; examples: aluminum hydroxide (constipating), magnesium hydroxide (osmotic, diarrhea-promoting). Often combined to balance effects. **Timing:** Give **1–3 hours after meals and at bedtime**. **Critical:** **Separate antacids from OTHER medications by 1–2 hours** (they impair absorption of many drugs: antibiotics, bisphosphonates, iron, digoxin, fluoroquinolones). **Mucosal protectants:** **Sucralfate 1 g four times daily (QID)** on an **EMPTY stomach** (1 hour before meals and at bedtime). Forms a protective gel-like barrier over the ulcer bed. **Crucial:** **Separate sucralfate from other drugs and antacids by 1–2 hours** (impairs absorption; does not interact with PPIs/H2 blockers as much).

**PUD Complications:** (1) **Hemorrhage**—erosion into an artery; presents with hematemesis/melena; managed initially with endoscopic hemostasis (clipping, cautery, epinephrine injection, variceal banding) and IV PPI; if endoscopy fails or patient is unstable, surgical angiography/embolization or gastrectomy may be needed. (2) **Perforation**—ulcer erodes fully through the gastric/duodenal wall; **sudden onset rigid, board-like abdomen with peritoneal signs**; a **surgical emergency** requiring immediate NPO status, NG decompression, broad-spectrum antibiotics, and operative closure (simple suture + omental patch, or partial gastrectomy for large gastric ulcers). (3) **Gastric outlet obstruction**—chronic ulcer scarring narrows the pyloric channel; presents with early satiety, postprandial vomiting, weight loss, and dehydration; may be managed medically (PPI + prokinetics) or surgically (endoscopic dilation or bypass). **GERD Complications:** (1) **Barrett's esophagus**—premalignant metaplasia from chronic acid exposure; requires long-term PPI therapy and periodic (2–3 year) endoscopic surveillance for dysplasia/cancer development. (2) **Esophageal stricture**—fibrotic narrowing from repeated reflux injury; managed with endoscopic dilation and high-dose PPI therapy. (3) **Aspiration pneumonia**—from nocturnal reflux and inadequate airway protection; prevent with proper positioning, slow feeding, and reflux control. **Hiatal Hernia Complications:** Rolling/paraesophageal hernia with **volvulus or strangulation** is a surgical emergency; presents with severe epigastric pain, vomiting, hematemesis, and shock; requires immediate surgical exploration and often Nissen fundoplication. **Recognizing surgical candidates:** Sudden severe symptoms (perforation, strangulation), signs of shock, or peritoneal signs indicate **operative urgency**.

**Dumping syndrome** (early dumping, occurring 10–20 minutes post-meal; late dumping, 1–3 hours post-meal) follows **gastrectomy or vagotomy**, when the normal pyloric sphincter function is bypassed or diminished. Hyperosmolar chyme rapidly enters the small intestine, drawing fluid into the lumen (osmotic diarrhea) and causing **cramping, bloating, diarrhea** (early dumping) and **reactive hypoglycemia with tremor, palpitations, anxiety** (late dumping from excessive insulin response). **Prevention/management:** Teach patients to **eat small frequent low-carbohydrate meals; avoid simple sugars and milk; take fluids BETWEEN meals (not with meals)** to reduce osmolarity. Severe cases may require octreotide (somatostatin analog) or revision surgery. **Iron-deficiency anemia** from chronic PUD bleeding or post-gastrectomy (reduced intrinsic factor, reduced stomach acid for iron dissolution) requires **iron supplementation** (oral ferrous sulfate 325 mg once daily with vitamin C for enhanced absorption; separate from PPIs/antacids by 2 hours) and dietary counseling (red meat, fortified cereals). Monitor hemoglobin every 3–6 months.

**PUD & GERD patient education essentials:** (1) **Medication adherence:** Take PPIs 30–60 minutes before breakfast; complete the FULL *H. pylori* eradication course (all 14 days) even if symptoms resolve (incomplete therapy drives antibiotic resistance). (2) **NSAID/aspirin avoidance:** These inhibit protective prostaglandins; if pain control is necessary, use acetaminophen instead; if NSAID is unavoidable (e.g., severe arthritis), take with a PPI. (3) **Lifestyle:** Smoking cessation (impairs mucosal blood flow), alcohol limitation, stress management, weight loss if overweight. (4) **Diet:** Small frequent meals; identify and avoid personal trigger foods (fatty, fried, spicy, caffeinated, chocolate, alcohol, citrus); avoid eating within 3 hours of bedtime. (5) **Positioning:** Sleep with head elevated 15–20 cm for GERD. **Red-flag symptoms requiring immediate medical attention:** (1) **Black tarry stools (melena)** or **vomiting blood/coffee-ground material**—suggests active bleeding. (2) **Sudden severe abdominal pain with rigid "board-like" abdomen**—perforation. (3) **Dizziness, syncope, or severe dyspnea**—signs of shock from hemorrhage. (4) **Persistent dysphagia**—may indicate stricture or malignancy. (5) **Unexplained weight loss**—raises concern for malignancy or outlet obstruction. Patients must understand that these warrant emergency evaluation, not home management with antacids.

This is a pathologic progression where untreated GERD's chronic injury leads to metaplasia, increasing cancer risk ~1000-fold. This relationship justifies long-term PPI therapy and surveillance.

H. pylori infection (especially in autoimmune gastritis) causes parietal cell atrophy, leading to loss of intrinsic factor, a protein required for B12 absorption in the terminal ileum. Without it, megaloblastic anemia and neurologic damage ensue, necessitating lifelong IM B12 therapy.

NSAIDs block cyclooxygenase (COX-1 and COX-2), reducing prostaglandins that regulate mucus secretion, bicarbonate production, and mucosal blood flow. This protective mechanism fails, enabling acid to erode the mucosa.

The primary defect (LES dysfunction) cascades into clinical manifestations. Lifestyle modifications (HOB elevation, small meals) address the mechanism, whereas acid suppression (PPIs) treats the secondary injury.

Different GI pathologies lead to different anemias: iron-deficiency from bleeding (requires oral iron therapy) versus B12-deficiency from intrinsic factor loss (requires IM injections). Diagnosis and management differ accordingly.

Chronic PUD can scar the pyloric region, narrowing the outlet. This functional obstruction impairs food passage, causing mechanical symptoms and secondary metabolic complications (dehydration, hypokalemia, hypochloremia).

Rolling hiatal hernias carry risk of twisting and strangulation (unlike sliding hernias, which are usually benign). Vascular compromise rapidly progresses to life-threatening complications, necessitating urgent surgical intervention.

Acute hemorrhage rapidly depletes intravascular volume. Compensatory tachycardia and vasoconstriction maintain perfusion initially, but if bleeding continues, shock ensues, affecting the brain, heart, and kidneys. ABC interventions interrupt this cascade.

PPIs suppress H. pylori growth; testing while on PPIs yields false-negatives, masking active infection and allowing treatment failure. This relationship emphasizes the critical importance of pre-test medication discontinuation.

NGT safety hinges on correct placement verification and patient positioning. Malplacement or low HOB elevation can lead to pulmonary aspiration, a serious complication. The relationship between verification method and safety outcomes is critical for practice.